Brain stimulation study seeks blood clues to depression treatment success

NCT ID NCT07673913

Not yet recruiting Knowledge-focused Sponsor: Gulhane Training and Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study looks at how a non-invasive brain stimulation technique called intermittent theta burst stimulation (iTBS) affects symptoms and blood markers in people with treatment-resistant depression. Fifty patients will receive iTBS sessions over four weeks, while fifty healthy volunteers provide baseline comparisons. Researchers will measure changes in depression severity and analyze blood samples for inflammatory and brain-health markers to better understand why some people respond to this treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Intermittent theta burst stimulation (iTBS) via transcranial magnetic stimulation device
What this could lead to: If successful, this could identify blood markers that predict who will benefit from TMS, paving the way for personalized depression treatment.
What could go wrong: This is a small, early-stage study focused on understanding mechanisms, not proving a new treatment. Results may not apply to all patients with depression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSION TREATMENT RESISTANT DEPRESSION (TRD)

Contacts and locations

Locations

Gulhane Training and Research Hospital

Ankara, Ankara, 06000, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.